Primary liver cancer
Conditions
Interventions
Group 1:HAIC+lenvatinib
Sponsors
Affiliated Tumor Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-75 years, regardless of gender 2. Patients with Barcelona clinical liver cancer (BCLC) were classified as stage B or stage C and were unresectable primary liver cancer; 3. Patients with child Pugh A / B liver function; 4. Patients with ECoG score of 0 or 1; 5. Patients with primary liver cancer confirmed by histopathology or clinic.
Exclusion criteria
Exclusion criteria: 1. Patients who have received any systemic chemotherapy or molecular targeted therapy for HCC, such as sorafenib; 2. Patients with any contraindications to TACE, rivatinib, oxaliplatin, calcium folinate or fluorouracil; 3. Patients with poor compliance can not follow the treatment process and follow-up; 4. Patients with severe heart, brain or kidney diseases; 5. Patients with history of organ transplantation; 6. Patients with known history of HIV infection; 7. Patients who had any life-threatening bleeding events within 30 days before enrollment, including transfusion therapy, surgery or local treatment, and continuous drug treatment; 8. Patients with uncontrolled or refractory ascites, persistent variceal bleeding or hepatic encephalopathy; 9. Patients with known central nervous system tumors, including metastatic brain diseases; 10. Patients who are known or suspected to be allergic to the study drug or any drug related to this trial; 11. Pregnant or lactating patients. A fertile woman must have a negative pregnancy test within 7 days before starting the drug study. Male and female participants in this trial must take adequate barrier contraceptive measures during the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Adverse reactions; | — |
Countries
China
Contacts
Public ContactFeixiang Wu
Cancer Hospital Affiliated to Guangxi Medical University
Outcome results
None listed